The Mayo Clinic Center for Individualized Medicine in Rochester, Minn., has joined forces with molecular diagnostics company Transplant Genomics to develop diagnostic tests to help detect whether a patient may reject transplanted kidneys.
The test is geared toward personalized immunosuppresion for solid organ transplant patients.
"Genomic analysis of blood can reveal early signs of rejection in transplanted kidneys," said Mark Stegall, MD, a Mayo-affiliated principal investigator in the research project. "The potential clinical utility is to be able to monitor for rejection more frequently than is possible with surveillance biopsies and to individualize immunosuppresion in transplant recipients."
In addition to research, the collaboration includes an assessment of Transplant Genomics' TruGraf test for rental transplant monitoring, an undisclosed Mayo Clinic investment in TGI and co-development of new tests and technologies for other transplant targets.
More articles on genomics:
The ethics of genomics: 4 explorations
How the Energy Department's supercomputers are aiding the Cancer Moonshot
Genomic sequencing can help determine end of a TB outbreak